Williams, Michael E <br/><br/>
Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  Nov 2006 
 - 7435-43 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0022-1767 
<br/><br/><label>Standard No.: </label>10.4049/jimmunol.177.10.7435  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antigens, CD20--blood<br/>Antineoplastic Agents--administration & dosage<br/>Complement C3--metabolism<br/>Dose-Response Relationship, Immunologic<br/>Drug Administration Schedule<br/>Drug Delivery Systems<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Leukemia, Lymphocytic, Chronic, B-Cell--blood<br/>Lymphocyte Count<br/>Lymphocyte Depletion<br/>Male<br/>Middle Aged<br/>Rituximab